These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 9232311)

  • 1. Symposium on ergonomics in drug delivery.
    Orser B; Doyle DJ; Futers L
    Can J Anaesth; 1997 Jul; 44(7):782-3. PubMed ID: 9232311
    [No Abstract]   [Full Text] [Related]  

  • 2. Reducing medication errors.
    Orser B
    CMAJ; 2000 Apr; 162(8):1150-1. PubMed ID: 10789632
    [No Abstract]   [Full Text] [Related]  

  • 3. Similar drug names cause concern.
    Carter AO
    Can Fam Physician; 1993 Apr; 39():754. PubMed ID: 8495131
    [No Abstract]   [Full Text] [Related]  

  • 4. Teaching hospitals to track, prevent drug errors.
    Koska MT
    Hospitals; 1992 Jan; 66(2):69-70. PubMed ID: 1729159
    [No Abstract]   [Full Text] [Related]  

  • 5. Cisapride and patient information leaflets.
    Sukkari SR; Sasich LD
    CMAJ; 2001 May; 164(9):1276-8; author reply 1278-9. PubMed ID: 11341134
    [No Abstract]   [Full Text] [Related]  

  • 6. Secondary pharmaceuticals manufacturing.
    Burling JN; Shah PV
    Occup Med; 1997; 12(1):29-48. PubMed ID: 9153051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trademark attorneys enlist pharmacists in the battle to prevent medication errors.
    Di Domizio G
    Hosp Pharm; 1995 Jan; 30(1):47-51. PubMed ID: 10184257
    [No Abstract]   [Full Text] [Related]  

  • 8. Think about drug packaging.
    Prescrire Int; 2012 Dec; 21(133):284. PubMed ID: 23373090
    [No Abstract]   [Full Text] [Related]  

  • 9. Needleless emergency drug system needs better differentiation from regular prefilled syringes; what an improvement!
    Cohen MR
    Hosp Pharm; 1994 Nov; 29(11):1018-9. PubMed ID: 10138577
    [No Abstract]   [Full Text] [Related]  

  • 10. Lessons from cisapride.
    CMAJ; 2001 May; 164(9):1269, 1271. PubMed ID: 11341130
    [No Abstract]   [Full Text] [Related]  

  • 11. Medication errors: an analysis comparing PHICO's closed claims data and PHICO's Event Reporting Trending System (PERTS).
    Benjamin DM; Pendrak RF
    J Clin Pharmacol; 2003 Jul; 43(7):754-9. PubMed ID: 12856390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Avoiding drug errors. Reporting of critical incidents shows how errors occur.
    Nandwani N
    BMJ; 1995 Nov; 311(7016):1368. PubMed ID: 7496299
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug labelling and a near miss in the labour suite.
    Murdoch JA; Lane J; Goldstein DH
    Can J Anaesth; 2004 Oct; 51(8):854-5. PubMed ID: 15470184
    [No Abstract]   [Full Text] [Related]  

  • 14. Current good manufacturing practice in manufacturing, processing, packing, or holding of drugs; revision of certain labeling controls--FDA. Final rule.
    Fed Regist; 1993 Aug; 58(147):41348-54. PubMed ID: 10127711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2010 drug packaging review: identifying problems to prevent errors.
    Prescrire Int; 2011 Jun; 20(117):162-5; discussion 165. PubMed ID: 21678710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Red sky in the morning: modifying prescription drug labels as a result of postmarket surveillance.
    Jacobson JD; Feigal D
    Food Drug Law J; 2007; 62(3):529-46. PubMed ID: 17915395
    [No Abstract]   [Full Text] [Related]  

  • 17. Bringing the FDA's Information to Market.
    Woloshin S; Schwartz LM
    Arch Intern Med; 2009 Nov; 169(21):1985-7. PubMed ID: 19933960
    [No Abstract]   [Full Text] [Related]  

  • 18. A quantitative analysis of adverse events and "overwarning" in drug labeling.
    Duke J; Friedlin J; Ryan P
    Arch Intern Med; 2011 May; 171(10):944-6. PubMed ID: 21606101
    [No Abstract]   [Full Text] [Related]  

  • 19. Current good manufacturing practice in manufacturing, processing, packing, or holding of drugs; revision of certain labeling controls. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2012 Mar; 77(54):16158-63. PubMed ID: 22479732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Invited commentary--prescription drug label adverse events: a call for prioritization: comment on "A quantitative analysis of adverse events and 'overwarning' in drug labeling".
    Cheng C; Guglielmo BJ
    Arch Intern Med; 2011 May; 171(10):946-7. PubMed ID: 21606102
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.